Recent and ongoing studies in pediatric AML without information on treatment outcome but with guidelines on risk-group stratified allo-SCT or not
| Group/study . | Period . | Risk groups, % . | Low risk . | Standard risk . | High risk . | Who underwent allo-SCT . |
|---|---|---|---|---|---|---|
| AIEOP LAM 2002 | December 2002 to December 2009 | LR, 18; HR, 82 | Isolated t(8;21), inv(16)/t(16;16), and CR after course 1 | — | All others | HR patients; SR patients after relapse only |
| AML-BFM 200415 | March 2004 to December 2009 | LR, 30; HR, 70 | FAB M1/M2 with Auer rods, FAB M4Eo+, t(8;21), inv(16), and blasts on day 15 < 5% and absence of FLT3/ITD | — | All patients who are not low risk | HR patients (until 2006); afterward no patients in CR1 |
| St Jude AML0830 | March 2008-2013 | LR, 31; SR, 32; HR, 37 | t(8;21) or inv(16) or t(16;16) and good response to therapy | All others | t(6;9), t(8;16), t(16;21), −7, −5, or 5q−, FLT3-ITD unless MRD negative after induction course I, FAB M0 or M6, FAB M7 without t(1;22), treatment related-AML, RAEB-2 or secondary AML after MDS, patients with poor response to therapy (MRD > 5% at day 22, and/or MRD > 0.1% after induction course II) | HR patients; also eligible for natural killer cell therapy, like SR patients |
| NOPHO-AML 200425 | January 2004- 2014 | LR, 80; HR, 20 | Less than 15% blasts after the first and CR after the second course, or t(8;21), inv(16), t(16;16), t(9;11) and CR after the second course | — | 11q23 abnormalities other than t(9;11), > 15% blasts at day 15, or lack of remission after 2 courses of chemotherapy | HR patients |
| COG AAML053118 | August 2006-2010 | LR, 25; SR, 57; HR, 18 | t(8;21), inv(16), t(16;16) | All others | −7, −5, −5q; bone marrow M3 (> 15% blasts) after course 1, except for those with low risk cytogenetics | SR and HR patients |
| ELAM0223 | March 2005-2012 | LR, 14; SR, 81; HR, 5 | t(8;21) | All others | −7, −5q, t(9;22), t(6;9) | SR and HR patients |
| JPLSG AML-05 | November 2006-2013 | LR, 40; SR, 40; HR, 20 | t(8;21), inv(16), t(16;16) | All others | −7, −5q, t(9;22), t(16;21), FLT3/ITD, no CR after course 1 | HR patients |
| MRC/DCOG AML 15 | March 2005 to February 2010 | LR, 30; SR, 55; HR, 15 | t(8;21) and inv(16)/t(16;16), irrespective of marrow status after first course or the presence of other genetic abnormalities | All others | More than 15% blasts after the first course, or adverse cytogenetics [−5, −7, del(5q), abn(3q), t(9;22), complex karyotype] | HR patients |
| Group/study . | Period . | Risk groups, % . | Low risk . | Standard risk . | High risk . | Who underwent allo-SCT . |
|---|---|---|---|---|---|---|
| AIEOP LAM 2002 | December 2002 to December 2009 | LR, 18; HR, 82 | Isolated t(8;21), inv(16)/t(16;16), and CR after course 1 | — | All others | HR patients; SR patients after relapse only |
| AML-BFM 200415 | March 2004 to December 2009 | LR, 30; HR, 70 | FAB M1/M2 with Auer rods, FAB M4Eo+, t(8;21), inv(16), and blasts on day 15 < 5% and absence of FLT3/ITD | — | All patients who are not low risk | HR patients (until 2006); afterward no patients in CR1 |
| St Jude AML0830 | March 2008-2013 | LR, 31; SR, 32; HR, 37 | t(8;21) or inv(16) or t(16;16) and good response to therapy | All others | t(6;9), t(8;16), t(16;21), −7, −5, or 5q−, FLT3-ITD unless MRD negative after induction course I, FAB M0 or M6, FAB M7 without t(1;22), treatment related-AML, RAEB-2 or secondary AML after MDS, patients with poor response to therapy (MRD > 5% at day 22, and/or MRD > 0.1% after induction course II) | HR patients; also eligible for natural killer cell therapy, like SR patients |
| NOPHO-AML 200425 | January 2004- 2014 | LR, 80; HR, 20 | Less than 15% blasts after the first and CR after the second course, or t(8;21), inv(16), t(16;16), t(9;11) and CR after the second course | — | 11q23 abnormalities other than t(9;11), > 15% blasts at day 15, or lack of remission after 2 courses of chemotherapy | HR patients |
| COG AAML053118 | August 2006-2010 | LR, 25; SR, 57; HR, 18 | t(8;21), inv(16), t(16;16) | All others | −7, −5, −5q; bone marrow M3 (> 15% blasts) after course 1, except for those with low risk cytogenetics | SR and HR patients |
| ELAM0223 | March 2005-2012 | LR, 14; SR, 81; HR, 5 | t(8;21) | All others | −7, −5q, t(9;22), t(6;9) | SR and HR patients |
| JPLSG AML-05 | November 2006-2013 | LR, 40; SR, 40; HR, 20 | t(8;21), inv(16), t(16;16) | All others | −7, −5q, t(9;22), t(16;21), FLT3/ITD, no CR after course 1 | HR patients |
| MRC/DCOG AML 15 | March 2005 to February 2010 | LR, 30; SR, 55; HR, 15 | t(8;21) and inv(16)/t(16;16), irrespective of marrow status after first course or the presence of other genetic abnormalities | All others | More than 15% blasts after the first course, or adverse cytogenetics [−5, −7, del(5q), abn(3q), t(9;22), complex karyotype] | HR patients |
FAB indicates French-American, British; RAEB, refractory anemia with excess blasts; NOPHO, Nordic Society of Pediatric Hematology and Oncology; MRC, Medical Research Council; and DCOG, Dutch Childhood Oncology Group.